Results 91 to 100 of about 8,864 (209)

Hematological neoplasms after PRRT: experience from long term follow-up of 173 patients in a tertiary center

Endocrine Oncology
Objective: Peptide receptor radionuclide therapy (PRRT) with lutetium-177 DOTATATE (177Lu-DOTATATE) is widely adopted as a later-line treatment (second-line or subsequent therapy) for patients with somatostatin receptor-positive neuroendocrine neoplasm ...
Joao Pedro Thimotheo Batista, Michael De La Iglesia, Hyun Kim, Vikas Prasad, Ravindra Shubha, Rama Suresh, Shuang Wu, Jingxia Liu, Meagan Jacoby, Samuel Urrutia, Nikolaos A Trikalinos   +10 more
doaj   +1 more source

Terapia metabólica con 177Lu-Dotatate en tumores avanzados que expresan receptores de somatostatina [PDF]

, 2021
Se trata de un estudio observacional basado en la experiencia del Servicio de Medicina Nuclear del Hospital Clínico Universitario de Santiago de Compostela, con la aplicación de una nueva terapia metabólica con 177Lu-Dotatate (Lutathera®).
Abou Jokh Casas, Estephany
core  

The role of somatostatin analogues on the therapeutic radiation dose in peptide receptor radionuclide therapy of NET with 177Lu -DOTATATE

, 2019
Diese Arbeit beschäftigt sich mit der Auswirkung einer prä-therapeutischen medikamentösen Somatostatin-Analoga (SSA) Therapie auf die therapeutische Strahlendosis von 177Lu-DOTATATE bei neuroendokrinen Tumoren (NET). Zum momentanen Zeitpunkt ist es nicht
Scheiber, Max
core   +2 more sources

177Lu-DOTATATE and 177Lu-prostate-specific membrane antigen therapy in a patient with advanced metastatic radioiodine-refractory differentiated thyroid cancer after failure of tyrosine kinase inhibitors treatment

World Journal of Nuclear Medicine, 2019
Patients with radioiodine-refractory differentiated thyroid cancer (RrDTC) have only a limited or no benefit from radioiodine therapy. For these patients, tyrosine kinase inhibitors have demonstrated encouraging results in advanced RrDTC.
Majid Assadi, Hojjat Ahmadzadehfar
doaj   +1 more source

Cost-Effectiveness of [177Lu]Lu-DOTATATE for the Treatment of Newly Diagnosed Advanced Gastroenteropancreatic Neuroendocrine Tumors: An Analysis Based on Results of the NETTER-2 Trials [PDF]

The recently published results of the NETTER-2 trial suggest the use of [177Lu]Lu-DOTATATE as a new standard of care in first-line therapy of patients with grade 2 or 3, well-differentiated, advanced gastroenteropancreatic neuroendocrine tumors.
Mansour, Nabeel, Unterrainer, Marcus, Holzgreve, Adrien, Mehrens, Dirk, Tiling, Maximilian, Brendel, Matthias, Ricke, Jens, Unterrainer, Lena M, Spitzweg, Christine, Kunz, Wolfgang G   +9 more
core   +1 more source

First-in-human experience of radiopharmaceutical therapy with [177Lu]Lu-DOTATATE in patients with advanced multiple myeloma

EJNMMI Reports
Radiotheranostics using somatostatin receptor (SSTR)-targeted agents has transformed the management of neuroendocrine tumors, yet its application in other oncological entities remains unexplored.
Wendy Delbart, Marie Vercruyssen, Rachele Danieli, Clémentine Marin, Zéna Wimana, Nathalie Meuleman, Patrick Flamen, Erwin Woff, Ioannis Karfis   +8 more
doaj   +1 more source

Low-dose targeted radionuclide therapy synergizes with CAR T cells and enhances tumor response

Frontiers in Immunology
Ionizing radiation has garnered considerable attention as a combination partner for immunotherapy due to its potential immunostimulatory effects. In contrast to the more commonly used external beam radiation, we explored the feasibility of combining ...
Yanping Yang, Yanping Yang, Yogindra Vedvyas, Yogindra Vedvyas, Yago Alcaina, Ju Y. Son, Irene M. Min, Irene M. Min, Moonsoo M. Jin, Moonsoo M. Jin   +9 more
doaj   +1 more source

Intra-arterial administration boosts 177Lu-HA-DOTATATE accumulation in salvage meningioma patients

, 2022
Intravenous 177Lu-high-affinity (HA)-DOTATATE has shown promising results for the treatment of surgery- and radiotherapy-refractory meningiomas. We aimed to investigate the added value of intraarterial administration. Methods: Patients underwent at least
de Keizer, Bart, Bruijnen, Rutger C G, Lam, Marnix G E H, Vonken, Evert-Jan P A, Snijders, Tom J, Seute, Tatjana, Braat, Arthur Johannes Anthonius Theodorus   +6 more
core  

The therapeutic efficacy of 225Ac-DOTATATE in neuroendocrine tumors: a preliminary meta-analysis

Frontiers in Oncology
ObjectiveThis meta-analysis aims to evaluate the therapeutic efficacy and toxicity of 225Ac-DOTATATE in patients with metastatic neuroendocrine tumors (NETs).MethodsThis systematic review adheres to the Preferred Reporting Items for Systematic Reviews ...
Jiao Ma, Jiao Ma, Jiao Ma, Yang Ji, Yang Ji, Yang Ji, Zhihan Yao, Zhihan Yao, Zhihan Yao, Jiangchu Yangqing, Jiangchu Yangqing, Jiangchu Yangqing, Chunyin Zhang, Chunyin Zhang, Chunyin Zhang   +14 more
doaj   +1 more source

Contribution to the understanding of radionuclide therapy with 177Lu-DOTATATE: investigation of new potential indications, drug combinations and the underlying radiobiology

, 2023
The mechanism of action of peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE has not fully been elucidated yet nor its specific radiobiology.
Delbart, Wendy
core